Daré Bioscience to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 04 2019 - 8:00AM
Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s
health innovation, today announced that Sabrina Martucci Johnson,
President and Chief Executive Officer, will present at the H.C.
Wainwright 21st Annual Global Investment Conference being held
September 8-10, 2019 in New York, NY.
Ms. Johnson will present an overview of Daré and
provide an update on the Company’s lead clinical programs:
Ovaprene®, a potential first-in-category hormone-free, monthly
contraceptive solution; DARE-BV1, a novel solution-to-gel
formulation containing clindamycin phosphate 2%, an antibiotic used
to treat bacterial infections; and Sildenafil Cream, 3.6%, a novel
topical cream formulation of sildenafil, the active ingredient in
Viagra®, for the potential treatment of female sexual arousal
disorder (FSAD).
Details of the presentation
follow:
Event: H.C. Wainwright 21st
Annual Global Investment ConferenceDate: Monday,
September 9, 2019Time: 8:20 a.m. EDT
A live webcast of the presentation will be
available via the Investors section of the Company’s website at
https://ir.darebioscience.com/events-presentations. An archive
of the presentation will be available on the website for 10
business days.
Investors attending the conference who are
interested in meeting with Ms. Johnson should contact their H.C.
Wainwright representative to make arrangements.
About Daré Bioscience
Daré Bioscience is a clinical-stage
biopharmaceutical company committed to the advancement of
innovative products for women’s health. The company’s mission is to
identify, develop and bring to market a diverse portfolio of
differentiated therapies that expand treatment options, improve
outcomes and facilitate convenience for women, primarily in the
areas of contraception, vaginal health, sexual health, and
fertility.
Daré’s product portfolio includes potential
first-in-category candidates in clinical development: Ovaprene®, a
hormone-free, monthly contraceptive intravaginal ring; Sildenafil
Cream, 3.6%, a novel cream formulation of sildenafil to treat
female sexual arousal disorder utilizing the active ingredient in
Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin
phosphate 2% to treat bacterial vaginosis via a single application;
and DARE-HRT1, a combination bio-identical estradiol and
progesterone intravaginal ring for hormone replacement therapy
following menopause. To learn more about Daré’s full portfolio of
women’s health product candidates, and mission to deliver
differentiated therapies for women, please
visit www.darebioscience.com.
Daré may announce material information about its
finances, product candidates, clinical trials and other matters
using its investor relations website
(http://ir.darebioscience.com), SEC filings, press
releases, public conference calls and webcasts. Daré will use these
channels to distribute material information about the company, and
may also use social media to communicate important information
about the company, its finances, product candidates, clinical
trials and other matters. The information Daré posts on its
investor relations website or through social media channels may be
deemed to be material information. Daré encourages investors, the
media, and others interested in the company to review the
information Daré posts on its investor relations
website (https://darebioscience.gcs-web.com/) and to follow
these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any
updates to the list of social media channels the company may use to
communicate information will be posted on the investor relations
page of the company's website mentioned above.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:Lee
Roth Burns McClellan lroth@burnsmc.com 212.213.0006
OR
Media on behalf of Daré Bioscience, Inc.:Jake
Robison Canale Communications jake@canalecomm.com
619.849.5383
Source: Daré Bioscience
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2023 to Apr 2024